Please login to the form below

Not currently logged in
Email:
Password:

Galbraith settles with Cohn & Wolfe

Rebecca Galbraith has settled court proceedings issued by global public relations agency Cohn & Wolfe, where she used to be board director

Rebecca Galbraith has settled court proceedings issued by the global public relations agency Cohn & Wolfe (C&W), where she was previously a board director.

Galbraith had been dismissed on grounds of gross misconduct a month after she handed in her notice at the agency.

In the proceedings at the high court, C&W alleged that Galbraith "acted in breach of contract and fiduciary duty by misappropriating proprietary information belonging to Cohn & Wolfe and preparing to actively compete with the agency while sitting as a board director."

As reported in PR Week, Galbraith said: "Firstly I wish to apologise unreservedly to Cohn & Wolfe and WPP for my actions, but secondly I wish to the apologise to the Cohn & Wolfe team in London."

She continued: "I accept my conduct was in breach of my legal obligations. I acknowledge I removed proprietary information belonging to Cohn & Wolfe but confirm that I did not open or disseminate that information to any third parties."

Galbraith has paid an undisclosed settlement. Her apology follows those of fellow former board directors, Fiona McMillan, who settled out of court on April 20 and, Jeremy Clark, who settled out of court on April 16.

4th May 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hayward Medical Communications

Hayward Medical Communications has been supporting partners in every sector of the healthcare industry to deliver evidence-based, clinically relevant and...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics